BBB National Programs Decision Summaries
BBB National Programs provides summaries of all case decisions from the National Advertising Division (NAD), National Advertising Review Board (NARB), Children’s Advertising Review Unit (CARU), Direct Selling Self-Regulatory Council (DSSRC), and Digital Advertising Accountability Program (DAAP). Subscribe to receive a weekly wrap-up of published case decisions in your inbox.
- All
-
3/14/2014 - NAD Refers Advertising by Elements of Health Care to FTC for Further Review After Company Declines to Participate
The National Advertising Division has referred to the Federal Trade Commission advertising claims made by Elements of Health Care, LLC, for the company’s L’Arginine Plus dietary supplements. -
3/13/2014 - NAD Finds T-Mobile Can Support Broadcast Advertising for ‘Jump’ Program, Recommends Company Modify Website
The National Advertising Division has determined that T-Mobile USA, Inc., can support certain advertising claims for the company’s “Jump” program. However, NAD recommended the company modify its JUMP website to more clearly disclose deductibles that may apply if one’s phone is lost, damaged or stolen. -
3/13/2014 - NAD Recommends JJVC Discontinue ‘Stuck to My Eye’ Claim, but Finds Advertiser Can Support Certain Claims in Contact Lens Advertising
The National Advertising Division has recommended that Johnson & Johnson Vision Care, Inc. discontinue a comparative advertising claim that was based on study participants’ answers to a leading survey question. NAD determined, however, that the advertiser could support certain other claims made in advertising to eye-care professionals. -
3/11/2014 - NAD Recommends Sprint Modify, Discontinue Certain Comparative Claims, Following T-Mobile Challenge
The National Advertising Division has recommended that Sprint Corporation modify or discontinue certain comparative advertising claims made in print and online advertising for the company’s “Unlimited My Way” monthly service plan. -
2/14/2014 - NAD Recommends Chase Bank Modify Claims for Cash-Back Rewards Card
The National Advertising Division has recommended that Chase Bank USA, NA, modify certain claims made for the company’s Chase Freedom Rewards Credit Card in broadcast and Internet advertising. The claims at issue were challenged by Capital One Bank (USA), NA. -
2/11/2014 - NAD Recommends Trinity Sports Group Discontinue Certain Claims, Testimonials for ‘NeuroImpact’ Supplement
The National Advertising Division has recommended that Trinity Sports Group, LLC, discontinue certain claims for the company’s “NeuroImpact” dietary supplement, including claims that the product has been clinically tested. -
2/10/2014 - Pharmavite Discontinues Certain Claims for NatureMade Products, Action NAD Found Necessary
Pharmavite LLC, the maker of NatureMade Letter Vitamins, Fish Oil, Flaxseed Oil, CoQ10 and Diabetes Health Pack Supplements, has discontinued broadcast advertising that was the focus of a National Advertising Division inquiry and has said it will better disclose the source of its “#1 Pharmacist Recommended” claims. -
2/04/2014 - NAD Recommends Murad Modify ‘Environmental Shield’ Claim
The National Advertising Division has recommended that Murad, Inc. modify advertising for the company’s “Environmental Shield” products to avoid conveying the unsupported message that the Murad Rapid Age Spot and Pigment Lightening Serum product itself provides a protective barrier against environmental harm to the skin. -
1/30/2014 - NAD Refers Advertising Claims from Chicken of the Sea to Regulatory Agencies for Further Review
The National Advertising Division has referred to the Federal Trade Commission (FTC) and California regulatory agencies advertising claims made by Chicken of the Sea, Inc., for its Chicken of the Sea tuna products after the company declined to participate in proceeding before NAD. -
1/30/2014 - NAD Refers Advertising for Brain Research Labs ‘Procera AVH’ to FTC for Further Review
The National Advertising Division has referred to the Federal Trade Commission advertising claims made by Brain Research Labs, for Procera AVH, following the company’s failure to abide by the terms of an NAD decision.